Recruiting Clinical Trials

Displaying 81 - 90 of 227 result(s)
Study Title Condition Phase Location
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes. Relapse Remitting Multiple Sclerosis Phase 4
  • Country: 
    United States
  • Country: 
    Puerto Rico
A Double-blind, Placebo-controlled, Randomized Dose-ranging Trial to Investigate Efficacy and Safety of Intravenous MIJ821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subje ... Major Depressive Disorder With Suicidal Ideation With Intent Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Brazil
  • Country: 
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension Multiple Sclerosis (MS) Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Austria
  • Country: 
An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis Relapsing Multiple Sclerosis Phase 3
  • Country: 
    United States
  • Country: 
    Bulgaria
  • Country: 
    Canada
  • Country: 
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension Resistant Hypertension Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    France
  • Country: 
A Randomized, Participant and Investigator Blinded, Sponsor Open-label, Placebo-controlled, Single Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF) Heart Failure With Reduced Ejection Fraction (HFrEF) Phase 1
  • Country: 
    United States
  • Country: 
    Netherlands
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies o ... Relapsing Multiple Sclerosis Phase 3
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
    Greece
  • Country: 
A 24-month, Open-label, Prospective, Multicenter Interventional, Single-arm Study Assessing the Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Relapsing Multiple Sclerosis (RMS) Patients in China Relapsing Multiple Sclerosis (RMS) Phase 4
  • Country: 
    China
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib Relapsing Multiple Sclerosis Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Belgium
  • Country: 
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament ... Relapsing-Remitting Multiple Sclerosis Phase 4
  • Country: 
    United States
  • Country: 
    Canada